Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P21810
UPID:
PGS1_HUMAN
Alternative names:
Bone/cartilage proteoglycan I; PG-S1
Alternative UPACC:
P21810; D3DWU3; P13247
Background:
Biglycan, also known as Bone/cartilage proteoglycan I or PG-S1, is a protein encoded by the gene with accession number P21810. It plays a crucial role in the body, potentially involved in collagen fiber assembly. This process is vital for maintaining the structural integrity of connective tissues, making Biglycan a key player in the body's structural framework.
Therapeutic significance:
Biglycan is linked to Meester-Loeys syndrome and Spondyloepimetaphyseal dysplasia, X-linked, diseases characterized by severe skeletal abnormalities. Understanding the role of Biglycan could open doors to potential therapeutic strategies for these genetic disorders, offering hope for targeted treatments that could alleviate symptoms or even correct the underlying genetic defects.